J Mol Med 2010, 88 (11) : 1181–90 EpubPubMedCrossRef 25 Choi MR

J Mol Med 2010, 88 (11) : 1181–90. EpubPubMedCrossRef 25. Choi MR, Kim HY, Park JY, Lee TY, Baik CS, Chai YG, Jung KH, Park KS, Roh W, Kim KS, Kim SH: Selection of optimal passage of bone marrow-derived www.selleckchem.com/products/Cyt387.html mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010, 472: 94–98.PubMedCrossRef 26. Chang YJ, Tseng CP, Hsu LF, Hsieh TB, Hwang SM: Characterization of

two populations of mesenchymal progenitor cells in umbilical cord blood. Cell Biol Int 2006, 30: 495–499.PubMedCrossRef 27. Jiang T, Liu W, Lv X, Sun H, Zhang L, Liu Y, Zhang WJ, Cao Y, Zhou G: Potent in vitro chondrogenesis of CD105 enriched human adipose-derived stem cells. Biomaterials 2010, 31: 3564–3571.PubMedCrossRef 28. Ishimura D, Yamamoto N, Tajima K, Ohno A, Yamamoto Y, Washimi O, Yamada H: Differentiation of adipose-derived stromal vascular fraction culture cells into chondrocytes using the method of cell sorting with a MK-4827 mesenchymal stem cell marker. Tohoku GDC-0941 cost J Exp Med 2008, 216: 149–156.PubMedCrossRef 29. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernandez-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado MV, Perez-Simon JA, Hernandez-Rivas JM, San-Miguel JF, del Canizo MC: Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 2009,

23: 664–672.PubMedCrossRef 30. Yeh SP, Chang JG, Lin CL, Lo WJ, Lee CC, Lin CY, Chiu CF: Mesenchymal stem cells can be easily isolated from bone marrow of patients with various haematological malignancies but the surface antigens expression may be changed after prolonged ex vivo culture. Leukemia 2005, 19: 1505–1507.PubMedCrossRef 31. Yeh SP, Chang JG, Lo WJ, Liaw YC, Lin CL, Lee CC, Chiu CF: Hydroxychloroquine in vivo Induction of CD45 expression on bone marrow-derived mesenchymal stem cells. Leukemia 2006, 20: 894–896.PubMedCrossRef 32. Bian L, Guo ZK, Wang HX, Wang JS, Wang H, Li

QF, Yang YF, Xiao FJ, Wu CT, Wang LS: In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells. In Vivo 2009, 23: 21–27.PubMed 33. Zhi-Gang Z, Wei-Ming L, Zhi-Chao C, Yong Y, Ping Z: Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases. Leuk Lymphoma 2008, 49: 2187–2195.PubMedCrossRef 34. Zhao ZG, Li WM, Chen ZC, You Y, Zou P: Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Immunol Invest 2008, 37: 726–739.PubMedCrossRef 35. Jootar S, Pornprasertsud N, Petvises S, Rerkamnuaychoke B, Disthabanchong S, Pakakasama S, Ungkanont A, Hongeng S: Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Leuk Res 2006, 30: 1493–1498.

Comments are closed.